

# NUMBERS CRUNCHED

The Scrip 100 universe gathers FY 2018 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales



WHO GETS IN?

**TOP 100**

Companies based on pharmaceutical sales only for fiscal year 2018



**\$1M**

The threshold on drug sales or R&D spending to get into the Scrip 100



**\$549.4BN**

Combined pharma sales of Top 20

**\$790.9BN**

Combined pharma sales of Top 100



**1.1 MILLION**

People employed by the Top 20

**BMS CRACKED THE TOP 10, UP FROM 14 LAST YEAR**



Now BMS appears poised to continue its upward trajectory even as competitive pressure mounts against Opdivo.

## GEOGRAPHICAL SPLIT OF TOP 20 COMPANIES IN SCRIP 100 UNIVERSE



**9**

Europe



**9**

US



**1**

Asia



**1**


RoW

## R&D SPEND



\*Some companies do not report R&D expenditure; R&D spend not limited to Pharma only in all cases

## A CLOSER LOOK AT TOP 10



**TOP SPOT 2020**  
**PFIZER**  
\$50bn in pharma sales